Dr. Yijun Hua is an Associate chief physician and Advisor of Master's Degree students in the department of Nasopharyngeal Carcinoma at Sun Yat-sen University Cancer Center. Dr. Hua got his Bachelor and Master Degrees in Clinical Medicine at Tongji Medical Universty and a Ph.D Degree in Oncology at Sun Yat-sen University, China in 2003 and 2010, respectively. He has been working as a Radiation Oncologist in the Cancer Center of Sun Yat-sen University since 2006, and was appointed as attending doctor in 2010. He is an expert in radiotherapy, chemo-radiotherapy and radiotherapy combined with targeted & immunotherapy in Head and Neck cancer, especially for nasopharyngeal carcinoma. Beyond this, he is also expert in endoscopy guided mini-invasive surgery for nasopharyngeal carcinoma and other head and neck cancers, He takes in charge of delineating, designing and evaluating more than 500 IMRT treatment plans annually; performing more than 150 endoscopy guided mini-invasive surgery for nasopharyngeal carcinoma each year. His training experience as a visiting scientist at the University of Western Sydney University in Australia.  He has published more than 30 peer-reviewed papers, including some papers in renowned journals such as The Lancet, JCO, Annals of Oncology, Journal for Immunotherapy of Cancer, Cell Disease and Differentiation, BMC Cancer，Head & Neck, EJC, Aging(US), Cell Disease & Death, etc.
He is also an active member of Chinese Radiation Oncology Group-Immuno-radiotherapy (CROG-IR), Professional Committee of NPC of Guangdong Provincial Anticancer Association，Chinesisch-Deutsche Gesellschaft für Medizin. Dr. Hua organized and founded the Professional Committee of Clinical Innovation of Guangdong Association of Medical Consumables Management and was appointed the president.
Nasopharyngeal carcinoma early diagnosis, individualized combination therapy; Salvage mini-invasive surgery for residual/recurrent nasopharyngeal carcinoma and other head and neck cancer (1) 2019-present  Sun Yat-sen University Cancer Center, Guangzhou, P.R. China, Associate chief physician.  MD.,Ph.D. (Radiation oncology)
(2) 2014-2018    Sun Yat-sen University Cancer Center, Guangzhou, P.R. China, Attending Physician.  MD.,Ph.D. (Radiation oncology)
(3) 2013-2014    University of Western Sydney University, Visiting Scholar
(4) 2010-2013    Sun Yat-sen University Cancer Center, Guangzhou, P.R. China, Attending Physician.  MD.,Ph.D. (Radiation oncology)
(5) 2006-2009 Sun Yat-sen University Cancer Center, Guangzhou, P.R. China, resident   physician in training. (Radiation oncology)
(6) 2003-2006 Sun Yat-sen University, Guangzhou, P.R. China, MS. 
(7) 1998-2003 Tongji Medical Universty, Wuhan, P.R.China, Bachelor in Medicine. 1.You R, Liu YP, Xie YL, Lin C, Duan CY, Chen DP, Pan Y, Qi B, Zou X, Guo L, Cao JY, Zhang YN, Wang ZQ, Liu YL, Ouyang YF, Wen K, Yang Q, Xie RQ, Li HF, Duan XT, Ding X, Peng L, Chen SY, Liang JL, Feng ZK, Xia TL, Xie RL, Jiang R, Gu CM, Liu RZ, Sun R, Yang X, Liu LZ, Ling L, Liu Q, Ng WT, Hua YJ#, Huang PY# Chen MY# Hyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023 Feb 23:S0140-6736(23)00269-6. doi: 10.1016/S0140-6736(23)00269-6. Epub ahead of print. PMID: 36842439.
2.Xi Ding, Wei-Jing Zhang, Rui You, Xiong Zou, Zhi-Qiang Wang, Yan-Feng Ouyang, Lan Peng, You-Ping Liu, Chong-Yang Duan, Qi Yang, Chao Lin, Yu-Long Xie, Si-Yuan Chen, Yong-Long Liu, Chen-Mei Gu, Ruo-Qi Xie, Pei-Yu Huang, Ming-Huang Hong#, Yi-Jun Hua#, Ming-Yuan Chen#. Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study. DOI: 10.1200/JCO.22.01450 Journal of Clinical Oncology
3.Hua YJ#, Liu YL, Wen K, Kurts C, Wu H, Mei Q, Li J. Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy. Ann Oncol. 2022 Oct 7:S0923-7534(22)04188-6. doi: 10.1016/j.annonc.2022.10.002. Epub ahead of print. PMID: 36216192; PMCID: PMC9540702.
4.Hua Y, You R, Wang Z, Huang P, Lin M, Ouyang Y, Xie Y, Zou X, Liu Y, Duan C, Liu Y, Gu C, Liu R, Yang Q, Jiang R, Zhang M, Ding X, Chen S, Lin C, Sun R, Chen M. Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial. J Immunother Cancer. 2021 Nov;9(11):e003290. doi: 10.1136/jitc-2021-003290. PMID: 34782428; PMCID: PMC8593727.
5.Hua YJ#, Ou-Yang YF, Zou X, Xia L, Luo DH, Chen MY. The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma. Front Oncol. 2021 Sep 14;11:648637. doi: 10.3389/fonc.2021.648637. PMID: 34595104; PMCID: PMC8476902.
6.Lin M, Yang Q, You R, Zou X, Duan CY, Liu YP, Huang PY, Xie YL, Wang ZQ, Liu T, Chen SY, Hua YJ#, Chen MY#. Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas. Oral Oncol. 2021 Apr;115:105200. doi: 10.1016/j.oraloncology.2021.105200. Epub 2021 Feb 19. PMID: 33610003.
7.Lin M, Yang Q, Zou X, You R, Duan CY, Liu YP, Huang PY, Xie YL, Wang ZQ, Liu T, Chen SY, Hua YJ#, Chen MY#. Biopsy of distant metastasis is not a significant prognostic factor for synchronous metastatic nasopharyngeal carcinoma: a propensity score-matched analysis from the Surveillance Epidemiology and End-Results Registry. J Cancer. 2021 May 27;12(14):4424-4432. doi: 10.7150/jca.54686. PMID: 34093843; PMCID: PMC8176419.
8.Liao Y#, Hua Y#, Li Y#, Zhang C, Yu W, Guo P, Zou K, Li W, Sun Y, Wang R, Zuo Y, Sui S, Tian C, Hao J, Chen M, Hu S, Chen M, Long Q, Wang X, Zou L, Xie F, Guo W, Deng W. CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation. Cell Death Differ. 2020 Nov 8. doi: 10.1038/s41418-020-00656-0. Epub ahead of print. PMID: 33162555.
9.Long Q#, Hua Y#, He L, Zhang C, Sui S, Li Y, Qiu H, Tian T, An X, Luo G, Yan Y, Zhao A, Shi D, Xie F, Chen M, Zheng F, Deng W. Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase. Int J Biol Sci. 2020 Sep 25;16(15):3002-3017. doi: 10.7150/ijbs.45115. PMID: 33061812; PMCID: PMC7545719.

10.Yu W#, Hua Y#, Qiu H, et al. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer. Cell Death Dis. 2020;11(7):506. Published 2020 Jul 6. doi:10.1038/s41419-020-2701-z

Updated by International Office, Sun Yat-sen University Cancer Center